NIH Highlighted Topic: Biomarker Discovery and Validation for Alcohol-Related Cardiovascular Diseases
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on discovering and validating biomarkers for alcohol-related cardiovascular and cerebrovascular diseases (CVD). This highlighted topic supports multidisciplinary projects designed to improve early detection, risk prediction, disease phenotyping, prognosis, and mechanistic understanding of how alcohol exposure contributes to cardiovascular injury and disease progression.
NIH recognizes that alcohol-related cardiovascular disease is frequently underdiagnosed because current clinical assessments, imaging approaches, and commonly used biomarkers lack specificity for alcohol-associated pathology. The initiative is particularly interested in projects that distinguish alcohol-related disease mechanisms from non-alcohol-related or mixed etiologies using advanced biomarker strategies, AI-enabled analytics, multimodal datasets, and longitudinal population studies.
Companies developing cardiovascular biomarker platforms, AI-powered diagnostic systems, digital health monitoring technologies, predictive analytics tools, imaging technologies, EHR-integrated clinical analytics systems, or precision medicine platforms may be strong candidates for funding.
Areas of interest include alcohol-associated hypertension, atrial fibrillation, alcoholic cardiomyopathy, ischemic heart disease, ischemic stroke, hemorrhagic stroke, multimodal biomarker discovery, molecular phenotyping, digital biomarkers, imaging biomarkers, causal inference modeling, and sex-specific disease susceptibility analysis. NIH is also encouraging projects leveraging longitudinal cohorts, electronic health records (EHRs), Mendelian randomization, machine learning, and integrated multi-omics datasets to improve cardiovascular disease characterization and clinical translation.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported primarily by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which is seeking transformative innovations that improve alcohol-related cardiovascular disease detection, biomarker science, precision diagnostics, risk stratification, and individualized prevention and treatment strategies.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of cardiovascular biomarker technologies, AI analytics systems, precision diagnostics, digital monitoring tools, and translational cardiovascular research platforms related to alcohol-associated cardiovascular disease.
Eligible activities may include:
AI and machine learning platforms for alcohol-related cardiovascular disease risk prediction
Biomarker discovery and validation technologies for alcohol-associated cardiovascular injury
Multi-omics and systems biology analytics platforms
Digital biomarker and wearable cardiovascular monitoring systems
Imaging biomarkers and advanced cardiovascular imaging technologies
EHR-integrated cardiovascular analytics and phenotyping platforms
Precision diagnostics distinguishing alcohol-related versus non-alcohol-related CVD
Predictive analytics for ischemic stroke, atrial fibrillation, hypertension, and cardiomyopathy
Longitudinal cohort analysis and causal inference modeling systems
Mendelian randomization and population health analytics technologies
Sex-specific cardiovascular disease susceptibility and progression research platforms
Prognostic biomarker development for disease progression and treatment response
Clinical decision support systems for cardiovascular risk management
Remote patient monitoring and cardiovascular digital health technologies
Molecular pathway analysis and translational cardiovascular therapeutics research
Integrated imaging, molecular, physiological, and digital biomarker platforms
Prototype development, translational studies, and clinical validation research
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, laboratory testing, software engineering, cloud infrastructure, AI model development, cardiovascular imaging research, bioinformatics analysis, longitudinal cohort analytics, clinical trial preparation, wearable integration, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable cardiovascular or digital health solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
